1. Introduction {#sec1}
===============

Primary cutaneous melanoma (PCM) accounts for only 4% of all skin cancers, but it causes the greatest number of skin cancer-related deaths worldwide \[[@bib1]\]. As for other tumoural histotypes, it is important to appropriately predict PCM prognosis through reliable, validated prognostic biomarkers for patients\' counseling, tailoring appropriate postoperative treatment, and stratification in prospective clinical trials \[[@bib2]\].

The American Joint Committee on Cancer (AJCC) staging system is the most widely accepted and used approach to melanoma staging \[[@bib3]\]. Patients with early, locoregional disease are classified into distinct stages based on Breslow thickness (BT), ulceration, and the sentinel lymph node (SN) status, which, in turn, includes the number of positive lymph nodes after completion lymph node dissection (CLND) in the case of a positive sentinel node biopsy (SNB).

Recently two clinical trials, the Multicenter Selective Lymphadenectomy Trial-II and the German Dermatologic Cooperative Oncology Group study (DeCOG-SLT) challenged the need to perform lymphadenectomy, because this procedure does not impact on outcome and is not informative for staging the vast majority of patients \[[@bib4],[@bib5]\].

Nevertheless, SNB still remains a key procedure to appropriately stage patients and to select those who are candidate to novel treatments with immunotherapy and targeted therapy in the adjuvant setting \[[@bib6]\]. As a consequence, it is likely that the number of performed SNB will increase, and the surgical waiting lists will lengthen.

Currently, there are conflicting data on the maximum allowable time interval between PCM resection and the subsequent wide local excision (WLE) and SNB. Several experts in the field advocate performing the SNB as soon as possible, but this inevitably negatively affects the routine surgical activity. The surgeon waiting lists are long particularly for the small surgical interventions, and this could potentially affect the way these interventions are performed. In universal health-care systems covered by the national healthcare insurance, the urgency to perform as soon as possible the SNB can potentially push towards privately executed procedures and introducing disparities.

The Italian Melanoma Intergroup (IMI) core centres have prospectively collected database with specific information on diagnosis, histopathological characteristics, timing of surgical procedures, and melanoma-specific outcome.

The aim of this study was to investigate if time interval between the PCM primary excision (PE) and SNB is associated with disease-free (DFS) and overall survival (OS), in the largest cohort of PCM patients so far reported.

2. Materials and methods {#sec2}
========================

The approval to conduct the study was obtained from the local Ethical Committees of the participating centres. The study included consecutive patients with PCM diagnosed, treated, and followed-up prospectively in 6 IMI centres (Istituto Nazionale Tumori, Milan, Papa Giovanni XXIII Cancer Center, Bergamo, Dermatologic Clinic of the University of Florence, Veneto Institute of Oncology of Padua, Department of Dermatology of the University of Turin and Istituto Nazionale Tumori, Naples). Since before 1998, SNB was not routinely performed, and patients with PCM diagnosed before 1997 were not considered eligible. The clinical and pathological parameters extracted from the database included gender, date of birth, date of diagnosis of PCM, date of SNB, BT, ulceration, SN status, surgical procedures, systemic therapies, and follow-up, including date of relapse and death.

2.1. Surgical procedures {#sec2.1}
------------------------

Diagnosis of the primary melanoma was based on the excisional biopsy and histopathological examination in all cases. Excisional biopsy was performed with total thickness excision and a narrow margin, according to the Italian guidelines ([www.aiom.it](http://www.aiom.it/){#intref0010}).

In all IMI centres, SNB was performed according to international guidelines criteria. For patients operated up to 2009, according to AJCC staging 6th edition \[[@bib7]\], SNB was performed in PCM with BT \> 1.0 mm or in presence of risk factors as ulceration, Clark level IV or V, regression or mitosis \>1/mm^2^. For patients resected from 2009 up to 2013, SNB was considered, according to the AJCC staging 7th edition \[[@bib3]\], in PCM patients with BT \> 1.0 mm or in presence of risk factors such as ulceration, Clark level IV or V or mitosis \>1/mm^2^. For all patients, the WLE, with a margin of 1--2 cm depending on the BT, and the SNB were performed in the same setting. SNB was performed according to the triple technique and histopathological analysis of the SN was conducted according to the EORTC Melanoma Group Pathology Protocol \[[@bib8]\]. In the event of SNB positivity, a CLND was performed according to the international guidelines before the publication of MSLT2 and DeCOG-SLT trials \[[@bib4],[@bib5]\].

2.2. Statistical methods {#sec2.2}
------------------------

DFS was defined as the time between SNB and disease relapse or death from any cause. OS was defined as the time interval between SNB and death from any cause. Patients who had not relapsed/died or died were censored at the date of the last follow-up visit. Continuous variables were described using mean and standard deviation (SD), the median with the first and third quartile (Q1--Q3; interquartile range, IQR) and minimum and maximum values, whereas categorical variables were described using frequencies and percentages. Chi-square test (or Fisher\'s exact test as appropriate) and t-test (or analysis of variance as appropriate) were performed to compare the distributions of categorical and continuous variable, respectively. SNB timing was defined as the time between PE and SNB. According to the routine activity in IMI centres, patients who underwent SNB before 1998 or more than 4 months after the PE were excluded from the analysis. SNB timing was analysed according three modalities: as continuous variable accounting for a weekly increase, as categorical variable defined according to the number of months from surgery and as dichotomous variable according to the best cut-off discriminating the patients based on DFS, identified by a CART analysis. The effect of the SNB timing on DFS and OS was explored by Cox proportional hazard models, stratified by centre, and adjusted for the demographical and clinical prognostic characteristics. Results of the analysis were expressed as hazard ratios (HRs), adjusted HRs (aHRs) and 95% confidence intervals (95%CIs). The proportionality of hazards (PH) was assessed by means of the Kolmogorov-type supremum test and evaluating the statistical significance of the interaction of each covariate with time. In case of evidence of no PH for one or more variables, Cox model including also the interaction with time of these variables was developed, and HRs at 6 months, 1 and 5 years were provided.

Moreover, a sensitivity analysis according to the propensity score (PS) approach was performed. The PS was defined for each patient as the probability to undergo a delayed SNB (after the 32nd day from PE) given a set of observed characteristics (age, gender, BT, site of PCM and ulceration), which could have affected the decision of SNB timing. The estimate of PS was obtained by means of a logistic model having SNB timing as dependent variable. The Cox models exploring the SNB timing were adjusted for the PS and for the SN status.

Survival curves were estimated with the Kaplan--Meier (KM) method and compared using the log-rank test.

Statistical significance was set at P \< 0.05 for a bilateral test. Analysis was carried out using the SAS (Statistical Analysis System, SAS Institute, version 9.4) software and the R (The CRAN Project, Version 3.6.1) software.

3. Results {#sec3}
==========

Between January 1997 and March 2018, 12,112 consecutive patients with PCM were diagnosed in six IMI centres. Among them, 8953 patients were eligible for this analysis. [eFigure S1](#appsec1){ref-type="sec"} summarises the flow diagram of the study.

A comparison among centres in terms of demographic and clinical characteristics at diagnosis is reported in [eTable 1](#appsec1){ref-type="sec"}. The mean timing of SNB ranged from 22.6 days (SD 16.8) to 53.4 days (SD 29.1). [Table 1](#tbl1){ref-type="table"} shows the demographic and clinical characteristics according to the best cut-off of SNB timing identified by the CART analysis (i.e. 31 days). Overall, 2706 (30.2%) and 6247 (69.8%) patients underwent SNB within (early SNB) or after (delayed SNB) 31 days from the PE, respectively. The mean SNB timing was 15.6 days (SD 11.7) in the early SNB group and 62.1 days (SD 20.6) in the delayed SNB group. The proportion of patients with a positive SN was significantly higher in the early SNB group (30.5% and 24.1% for early and delayed SNB respectively, p \< 0.0001).Table 1Demographics and clinical characteristics according to best cut-off of SNB timing.Table 1VariableEarly SNB\
N = 2706Delayed SNB\
N = 6247Overall\
N = 8953p-value**Age at PE**0.2117Mean (SD)54.1 (15.9)54.6 (15.5)54.4 (15.6)Median (Q1--Q3)54.9 (41.7--66.6)55.1 (42.7--67.0)55.0 (42.5--66.9)Min -- Max0.4--93.00.0--93.30.0--93.3Missing011**Woman**1234 (45.6)2925 (46.8)4159 (46.5)0.2878**Site**\<0.0001Trunk1179 (43.6)3035 (48.6)4214 (47.1)Lower limb951 (35.2)1682 (26.9)2633 (29.4)Upper limb312 (11.5)795 (12.7)1107 (12.4)Head/neck217 (8.0)680 (10.9)897 (10.0)Other46 (1.7)51 (0.8)97 (1.1)Missing145**Breslow thickness**\<0.0001Mean (SD)2.8 (2.7)2.4 (2.6)2.5 (2.6)Median (Q1--Q3)2.0 (1.1--3.5)1.6 (1.0--3.0)1.7 (1.0--3.2)Min -- Max0.0--43.00.0--65.00.0--65.0Missing336**T stage**\<0.0001T1548 (20.3)1665 (26.7)2213 (24.7)T2867 (32.1)2138 (34.2)3005 (33.6)T3749 (27.7)1522 (24.4)2271 (25.4)T4539 (19.9)919 (14.7)1458 (16.3)Missing336**Ulceration**994 (39.8)1822 (30.7)2816 (33.4)\<0.0001Missing206321527**SNB timing**--Mean (SD)15.6 (11.7)62.1 (20.6)48.1 (28.2)Median (Q1--Q3)19.0 (0.0--27.0)60.0 (45.0--76.0)47.0 (28.0--68.0)Min -- Max0.0--31.032.0--121.00.0--121.0**SNB timing -- monthly categorisation**--One month from PE2557 (94.5)0 (0.0)2557 (28.6)Two months from PE149 (5.5)3206 (51.3)3355 (37.5)Three/four months from PE0 (0.0)3041 (48.7)3041 (34.0)**SN status**\<0.0001[∗](#tbl1fnlowast){ref-type="table-fn"}Negative1875 (69.3)4732 (75.7)6607 (73.8)Positive826 (30.5)1503 (24.1)2329 (26.0)Not found4 (0.1)12 (0.2)16 (0.2)Missing101**CLND in positive SN patients**0.0245Yes790 (97.8)1414 (96.0)2204No18 (2.2)59 (4.0)77Missing183048[^1][^2]

The median follow-up was 95.9 months (IQR 52.4--132.1). In the early SNB group, 788 (29.1%) patients relapsed, 854 (31.6%) died and 1045 (38.6%) relapsed or died without relapse (i.e. DFS events). In the delayed SNB group, 1096 (17.5%) patients relapsed, 1198 (19.2%) died and 1553 (24.9%) relapsed or died without relapse. [Table 2](#tbl2){ref-type="table"}, [Table 3](#tbl3){ref-type="table"} report the univariable and multivariable analyses on DFS and OS, respectively. For both end-points, evidence of no PH was found for age, site of PCM, ulceration and SN status. Moreover, no PH was detected for BT in the analysis on DFS and for SNB timing with monthly categorisation in the analysis on OS. At multivariable analysis, after adjusting for age, gender, BT, site, ulceration and the SN status, a delay in the timing of SNB was associated with a better DFS (aHR \[1 week increase\] 0.98, 95% confidence interval \[CI\] 0.97--0.99, p \< 0.0001) and OS (aHR \[1 week increase\] 0.98, 95%CI 0.97--0.99, p = 0.0006). Similar results were observed after adjusting for the interaction with time of variables with no PH.Table 2Effect of the SNB timing on relapse free survival. Univariate and multivariable Cox proportional hazard model stratified by centre.Table 2VariableUnivariate modelsMultivariable model 1Multivariable model 2Multivariable model 3HR \[95%CI\]p-valueHR \[95%CI\]p-valueHR \[95%CI\]p-valueHR \[95%CI\]p-value**SNB timing** (1 week increase)0.95 \[0.94--0.96\]\<0.00010.98 \[0.97--0.99\]\<0.0001--------**SNB timing**[∗](#tbl2fnlowast){ref-type="table-fn"} (ref. Month 1 after PE) Month 2 after PE0.74 \[0.68--0.81\]\<0.0001----0.83 \[0.75--0.91\]0.0001---- Month 3--4 after PE0.68 \[0.61--0.75\]\<0.0001----0.82 \[0.74--0.92\]0.0004----**SNB timing \>31 days**0.70 \[0.64--0.76\]\<0.0001--------0.81 \[0.74--0.88\]\<0.0001**Breslow thickness** (1 mm increase)1.08 \[1.08--1.09\]\<0.00011.06 \[1.05--1.07\]\<0.00011.06 \[1.05--1.07\]\<0.00011.06 \[1.05--1.07\]\<0.0001**Age at surgery**[∗](#tbl2fnlowast){ref-type="table-fn"} (1 year increase)1.03 \[1.03--1.03\]\<0.00011.03 \[1.02--1.03\]\<0.00011.03 \[1.02--1.03\]\<0.00011.03 \[1.02--1.03\]\<0.0001**Female sex**0.72 \[0.66--0.78\]\<0.00010.84 \[0.77--0.91\]\<0.00010.84 \[0.77--0.91\]\<0.00010.84 \[0.77--0.91\]\<0.0001**Site**[∗](#tbl2fnlowast){ref-type="table-fn"} (ref. Trunk) Lower limb1.02 \[0.93--1.12\]0.61310.98 \[0.89--1.08\]0.66840.98 \[0.89--1.09\]0.73380.98 \[0.89--1.08\]0.6871 Upper limb0.89 \[0.78--1.02\]0.08330.86 \[0.75--0.99\]0.03890.87 \[0.76--1.00\]0.04680.87 \[0.76--1.00\]0.0463 Head/neck1.63 \[1.44--1.84\]\<0.00011.60 \[1.41--1.81\]\<0.00011.60 \[1.41--1.82\]\<0.00011.61 \[1.41--1.82\]\<0.0001 Other3.41 \[2.56--4.55\]\<0.00011.88 \[1.40--2.54\]\<0.00011.88 \[1.40--2.54\]\<0.00011.87 \[1.39--2.53\]\<0.0001**Ulceration**[∗](#tbl2fnlowast){ref-type="table-fn"}2.97 \[2.73--3.22\]\<0.00012.05 \[1.88--2.23\]\<0.00012.06 \[1.90--2.25\]\<0.00012.06 \[1.89--2.24\]\<0.0001**SNB outcome**[∗](#tbl2fnlowast){ref-type="table-fn"} (ref. Absent) Positive2.57 \[2.37--2.78\]\<0.00012.14 \[1.96--2.33\]\<0.00012.15 \[1.97--2.34\]\<0.00012.14 \[1.96--2.34\]\<0.0001 Not found1.83 \[0.82--4.08\]0.14031.17 \[0.44--3.13\]0.75321.18 \[0.44--3.16\]0.73901.19 \[0.44--3.17\]0.7349[^3][^4][^5][^6]Table 3Effect of the time to SNB on overall survival. Univariate and multivariable Cox proportional hazard model stratified by centre.Table 3VariableUnivariate modelsMultivariable model 1Multivariable model 2Multivariable model 3HR \[95%CI\]p-valueHR \[95%CI\]p-valueHR \[95%CI\]p-valueHR \[95%CI\]p-value**SNB timing** (1 week increase)0.96 \[0.95--0.97\]\<0.00010.98 \[0.97--0.99\]0.0006--------**SNB timing**[∗](#tbl3fnlowast){ref-type="table-fn"} (ref. Month 1 after PE) Month 2 after PE0.73 \[0.66--0.81\]\<0.0001----0.76 \[0.69--0.85\]\<0.0001---- Month 3--4 after PE0.74 \[0.66--0.83\]\<0.0001----0.85 \[0.75--0.95\]0.0062----**SNB timing \>31 days**0.72 \[0.65--0.78\]\<0.0001--------0.78 \[0.71--0.85\]\<0.0001**Breslow thickness**[∗](#tbl3fnlowast){ref-type="table-fn"} (1 mm increase)1.09 \[1.09--1.10\]\<0.00011.07 \[1.06--1.08\]\<0.00011.07 \[1.06--1.08\]\<0.00011.07 \[1.06--1.08\]\<0.0001**Age at surgery**[∗](#tbl3fnlowast){ref-type="table-fn"} (1 year increase)1.04 \[1.04--1.04\]\<0.00011.04 \[1.03--1.04\]\<0.00011.04 \[1.03--1.04\]\<0.00011.04 \[1.03--1.04\]\<0.0001**Female sex**0.63 \[0.58--0.69\]\<0.00010.77 \[0.70--0.85\]\<0.00010.78 \[0.70--0.86\]\<0.00010.78 \[0.71--0.86\]\<0.0001**Site**[∗](#tbl3fnlowast){ref-type="table-fn"} (ref. Trunk) Lower limb0.88 \[0.80--0.98\]0.02020.85 \[0.75--0.95\]0.00380.85 \[0.76--0.95\]0.00370.84 \[0.75--0.94\]0.0025 Upper limb0.88 \[0.76--1.02\]0.10040.84 \[0.72--0.98\]0.02900.85 \[0.73--0.99\]0.03730.85 \[0.72--0.99\]0.0322 Head/neck1.45 \[1.27--1.67\]\<0.00011.36 \[1.18--1.57\]\<0.00011.36 \[1.18--1.58\]\<0.00011.37 \[1.18--1.58\]\<0.0001 Other3.31 \[2.43--4.51\]\<0.00011.83 \[1.33--2.52\]0.00021.83 \[1.33--2.52\]0.00021.81 \[1.32--2.50\]0.0003**Ulceration**[∗](#tbl3fnlowast){ref-type="table-fn"}3.12 \[2.85--3.42\]\<0.00012.16 \[1.96--2.38\]\<0.00012.18 \[1.98--2.40\]\<0.00012.17 \[1.97--2.38\]\<0.0001**SNB outcome**[∗](#tbl3fnlowast){ref-type="table-fn"} (ref. Absent) Positive2.51 \[2.30--2.75\]\<0.00012.03 \[1.84--2.24\]\<0.00012.07 \[1.87--2.28\]\<0.00012.03 \[1.84--2.24\]\<0.0001 Not found1.61 \[0.60--4.30\]0.34320.67 \[0.17--2.69\]0.57310.67 \[0.17--2.67\]0.56550.66 \[0.16--2.66\]0.5604[^7][^8][^9][^10][^11][^12]

A positive impact on DFS was found in patients who underwent SNB at the second or third/fourth month after the PE (aHR \[second versus first month\] 0.83 95%CI 0.75--0.91, p = 0.0001; aHR \[third/fourth versus first month\] 0.82 95%CI 0.74--0.92, p = 0.0004). Most importantly, a longer OS was observed in patients who underwent SNB at the second and third/fourth month after the PE (aHR \[second versus first month\] 0.76 95%CI 0.69--0.85, p \< 0.0001; aHR \[third/fourth versus first month\] 0.85 95%CI 0.75--0.95, p = 0.0062). Similar results on OS were observed after adjusting for the interaction with time of variables with no PH. [Fig. 1](#fig1){ref-type="fig"} A and B shows the KM curves according to the SNB timing for DFS and OS, respectively.Fig. 1Kaplan-Meier curves showing disease-free survival and overall survival according to SNB timing categorised monthly (A and B) and according to CART analysis (C and D). SNB, sentinel node biopsy; PE, primary excision.Fig. 1

Considering the cut-off defined according to the CART analysis, a SNB performed at least 32 days after the PE was associated with both a better DSF (aHR 0.81, 95%CI 0.74--0.88, p \< 0.0001) and OS (aHR 0.78, 95%CI 0.71--0.85, p \< 0.0001). Similar results were observed after adjusting for the interaction with time of variables with no PH or adjusting for the propensity score (DFS: aHR \[delayed versus early SNB\] 0.81, 95%CI 0.75--0.88, p \< 0.0001; OS: aHR \[delayed versus early SNB\] 0.80, 95%CI 0.73--0.88, p \< 0.0001). [Fig. 1](#fig1){ref-type="fig"}C and [D](#fig1){ref-type="fig"} show the KM curves for DFS and OS according to the cut-off determined by CART analysis.

[eTables 2 and 3](#appsec1){ref-type="sec"} report the HRs at 6 months, 1 and 5 years of variables with evidence of no PH. Although evidence of no PH, the variations of the HRs at 6 months, 1 and 5 years seem to be negligible.

Given the above results, we performed a subgroup analysis in patients with negative and positive SN, respectively. [Fig. 2](#fig2){ref-type="fig"} summarises the multivariable Cox analysis according to this subgroup analysis.Fig. 2**Subgroup analysis on disease-free survival and overall survival according to SN status**. SN, sentinel lymph node; SNB, sentinel node biopsy; PE, primary excision; CI, confidence interval; HR, hazards ratio.Fig. 2

In patients with a negative SN status, a beneficial impact of delayed SNB (i.e. at least 32 days after PE) was confirmed for DFS (aHR 0.70 95%CI 0.63--0.79, p \< 0.0001) and OS (aHR 0.69 95%CI 0.61--0.78, p \< 0.0001). In patients with a positive SN status, DFS (aHR \[delayed versus early SNB\] 0.96 95%CI 0.84--1.09, p = 0.5339) and OS (aHR \[delayed versus early SNB\] 0.94 95%CI 0.81--1.08, p = 0.3738) were not significantly different between patients with early or delayed SNB.

4. Discussion {#sec4}
=============

The most striking result of our study is that the interval between excision of a PCM and the SNB could have a prognostic impact in patients with a negative SN, being DFS and OS worse in patients who undergo early SNB, whereas no effect was found in patients with positive SN. In patients with negative SN, the delayed SNB procedure was associated with a 30% risk reduction of recurrence and/or death.

The results of our study could have some important clinical implications. From a clinical standpoint, our results do not support a strict time interval for WLE and SNB, and this notion could be important for national guidelines and to counsel patients and reduce the number of high urgency referrals.

In our series, a higher proportion of positive SN was found in early versus delayed SNB subgroup of patients (30.5% versus 24.1%). Moreover, patients who underwent an early SNB had a higher median BT (2.0 mm versus 1.6 mm) and more ulcerated melanomas (39.8% versus 30.7%). A positive SN was associated to well-known unfavourable prognostic factors, and we cannot exclude that physicians may have selected patients to get an early SNB owing to negative prognostic factors.

The results of the present study should be considered in the context of the current literature. To date, the impact of a longer time interval until SNB on DFS and OS has been reported in 11 studies \[[@bib9], [@bib10], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18], [@bib19]\], which included patients with negative and/or positive SN ([Table 4](#tbl4){ref-type="table"} ). The results so far reported are conflicting because of heterogeneity in patients\' characteristics, number of patients included according to the SN status, the time interval to SNB which varies from 7 to 59 days and finally, the median follow-up.Table 4Clinical studies investigating the impact of timing of sentinel lymph node biopsy on DFS and/or overall survival in melanoma patients.Table 4AuthorNumber of patientsCut-off for early/delayed time interval to SNB (days)Median follow-upMultivariable analysis on DFS (Cox proportional hazard model)Multivariable analysis on OS (Cox proportional hazard model)Fortes \[[@bib9]\]SN−: 607\
SN+:14130Not specifiedNot reportedSN−: HR \[Early versus delayed\]\
1.77, 95%CI 0.97--3.26\
SN+: HR \[Early versus delayed\]\
0.29, 95%CI 0.11--0.77 \[MSS\]Carpenter \[[@bib10]\]SN−: 412\
SN+: 6128 (A) and 56 (B)2.8 yearsA) HR \[Early versus delayed\] 1.01, 95%CI 0.64--1.58\
B) HR \[Early versus delayed\] 0.80, 95%CI 0.37--1.73A) HR \[Early versus delayed\] 1.05, 95%CI 0.61--1.82\
B) HR \[Early versus delayed\] 0.89, 95%CI 0.34--2.34Crawford \[[@bib11]\]723 (SN− and SN+)Analysed as continuous variable3.34 yearsNot reportedHR \[1 day increase\] 0.89, 95%CI 0.74--1.07\
\[OS calculated from the primary melanoma excision\]Oude Ophuis \[[@bib12]\]SN−: 2841\
SN+: 7054350 monthsNot reportedHR \[1 day increase\] 1.0, 95%CI 0.99--1.01Tejera-Vaquerizo \[[@bib13]\]SN−: 1498\
SN+: 4644046 monthsNot significant for SN− and SN+ (data not shown) \[DFS calculated from the excision of the primary melanoma plus 120 days\]SN−: HR \[Early versus delayed\] 2.6, 95%CI 1.5--4.6\
SN+: Not significant (data not shown) \[OS calculated from the excision of the primary melanoma plus 120 days. MSS\]Nelson \[[@bib14]\]SN−: 2051\
SN+: 4323095.7 monthsHR \[Early versus delayed\] 0.98, 95%CI 0.81--1.18)HR \[Early versus delayed\] 1.05, 95%CI 0.83--1.34\
\[MSS \]Tejera-Vaquerizo \[[@bib15]\]SN−: 274\
SN+: 66\
SN not found: 1040103 monthsHR \[Early versus delayed\] 1.68, 95%CI 1.07--2.65\
\[DFS calculated from primary excision. Propensity score matching\]HR \[Early versus delayed\] 1.77, 95%CI 1.11--2.83\
\[OS calculated from primary excision. Propensity score matching\]Richtig \[[@bib16]\]SN+: 1214342 monthsNot reportedNot reportedGambichler \[[@bib17]\]SN−: 667\
SN+: 2297Not specifiedNot reported\]Not reportedOude Ophuis \[[@bib18]\]SN+:10154736 monthsNot reportedHR \[1 day increase\] 1.0, 95%CI 0.99--1.01Parrett \[[@bib19]\]SN−: 414\
SN+: 784011.7 yearsHR \[Delayed versus early\] 0.91, 95%CI 0.64--1.28HR \[Delayed versus early\] 0.91, 95%CI 0.67--1.23\
\[MSS \][^13]

With regards to SN-positive patients, while Fortes *et al.* found a benefit of early SNB \[[@bib9]\], three other large studies did not \[[@bib12],[@bib13],[@bib18]\]. Specifically, Tejera-Vaquerizo \[[@bib13]\] reported that interval to SNB had no effects on survival in a SN-positive cohort of 464 patients. Similarly, in two large, well-conducted studies by the EORTC melanoma group, including 1015 and 705 patients, respectively, the interval between primary melanoma excision and SNB was not associated with survival in SN-positive patients. Our study confirms these findings \[[@bib12],[@bib18]\].

With regards to SN-negative cohorts, the results are still conflicting. In seven studies, the interval between primary melanoma excision and SNB was not associated with DFS and/or OS \[[@bib9], [@bib10], [@bib11], [@bib12],[@bib14],[@bib17],[@bib19]\]. More recently, Tejera-Vaquerizo *et al.* \[[@bib13]\], in a retrospective study including 1498 SN-negative patients, did find a detrimental effect of a short time interval on OS. Our study included 6607 SN-negative patients, and again a strong effect of time interval was found in this relatively low risk melanoma population.

Melanoma is an immunogenic cancer. Melanoma cells display multiple antigens and peptide epitopes that are targetable by the host immune system, and several immunotherapy strategies have been developed in the adjuvant and metastatic setting in the last decade.

Induction of a specific, clonal antitumour T-cell response depends on the priming of specific naıve T cells by antigen presenting cells in the draining lymph nodes \[[@bib20]\]. When a specific antigen is presented by antigen presenting cells, the naıve T cells are activated \[[@bib21]\]. Priming of helper and cytotoxic antitumour T cells seems to take place in the SN and potentially is associated with an antitumour T-cell response in melanoma.

Nevertheless, several steps are required for an efficient immune response including the transport, processing and presentation of melanoma antigens in the lymph nodes by antigen presenting cells, as well as the subsequent priming of tumour antigen--specific T cells. The SN is the first lymphoid organ that tumour antigens meet after being released from a primary tumour into the lymphatic drainage. SNs are thought to be more closely associated with antitumour immunity than non-SNs \[[@bib22]\]. However, the presence of melanoma inhibits an immune response by releasing immunosuppressive cytokines and creating an immunosuppressive microenvironment \[[@bib23],[@bib24]\]. After excision of primary melanoma, processing, maturation of antigen presenting cells, antigen presentation and priming require time. Indeed, an immune response requires precise coordination of molecular and cellular signaling, tightly regulated with multistep cascades, which occur over multiple time and length scales \[[@bib25]\]. Our results suggest that early excision of negative SN may, after removal of primary melanoma, impair and stop this process and is therefore associated with a worse DFS and OS. Nevertheless, the interval between melanoma development and the diagnostic biopsy is likely to be greater and more variable than the interval between biopsy and SNB. This interval, which is more difficult to measure, should be considered as well, and this represent an area of future translational and preclinical investigations.

This study adds novel information to the current literature for several reasons: 1) it is the largest analysis to date on the effect of timing of SNB on survival; 2) all included patients were treated in the context of IMI centres with homogeneous surgical procedures and similar schedule of follow-up; 3) a robust statistical analysis allowed us to evaluate the impact of timing to SNB through different models: i) timing to SNB as a continuous variable, ii) timing to SNB in discrete categories (months after primary resection), iii) and two different groups according to the CART analysis. Importantly, these results were confirmed by a sensitivity analysis according to the PS approach; 4) we provided a comprehensive overview of all studies to date published; 5) the median follow-up is one of the longest so far reported; and 6) our data suggest that a time interval until 4 months may be not detrimental for patients with both positive and negative SN.

We are also aware of some limitations, including 1) the retrospective nature of our analysis, which cannot exclude patient enrollment bias, 2) the histopathological review was not centralised among participating centres, which can increase heterogeneity in the characterization of tumour variables, 3) the lack of a validation cohort.

Our study, in the context of the current literature, has clinical implications considering that the number of performed SNBs will increase, as it is now a gateway to effective adjuvant therapy in stage III. Furthermore, the current COVID-19 pandemic may raise issues in the time schedule of surgical procedures.

In conclusion, our data do not support a strict time interval for SNB, and considering our results and those of previous studies, this notion should be incorporated in current guidelines and to counsel patients to reduce the number of high urgency referrals.
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[^1]: Early SNB, sentinel node biopsy performed within 31 days of primary excision; Delayed SNB, sentinel node biopsy performed at least 31 days after the primary excision; SNB, sentinel node biopsy; SN, sentinel node; PE, primary excision; CLND, complete lymph node dissection; SD, standard deviation; Q1--Q3, first quartile--third quartile.

[^2]: Comparison performed excluding patients with sentinel node not found.

[^3]: SNB, sentinel node biopsy; PE, primary excision; CI, confidence interval; HR, hazards ratio.

[^4]: Effect of 1 week increase of SNB timing adjusted for also the interactions with time of the variables with ∗ is HR \[1 week increase\] 0.98 \[95%CI 0.97--0.99\], p = 0.0001.

[^5]: Effect of SNB timing \>31 days adjusted for also the interactions with time of the variables with ∗ is HR 0.81 \[95%CI 0.75--0.89\], p \< 0.0001.

[^6]: Evidences of non-proportionality of hazards.

[^7]: SNB, sentinel node biopsy; PE, primary excision; CI, confidence interval; HR, hazards ratio.

[^8]: Effect of 1 week increase of SNB timing adjusted for also the interactions with time of the variables with ∗ is HR \[1 week increase\] 0.98 \[95%CI 0.97--0.99\], p = 0.0016.

[^9]: Effect of doing the SLNB during the second month from PE adjusted for also the interactions with time of the variables with ∗ is HR 0.77 \[95%CI 0.69--0.86\], p \< 0.0001.

[^10]: Effect of doing the SLNB during the third/fourth month from PE adjusted for also the interactions with time of the variables with ∗ is HR 0.86 \[95%CI 0.76--0.97\], p = 0.0125.

[^11]: Effect of SNB timing \>31 days adjusted for also the interactions with time of the variables with ∗ is HR 0.79 \[95%CI 0.72--0.86\], p \< 0.0001.

[^12]: Evidences of non-proportionality of hazards.

[^13]: MSS, melanoma-specific survival; SN, sentinel lymph node; SN−, negative sentinel lymph node; SN+, positive sentinel lymph node; SNB, sentinel lymph node biopsy; DFS, disease-free survival; OS, overall survival; HR, hazard ratio; 95%CI, 95% confidence interval.
